Therapeutic targeting of ACLY in T-ALL in vivo is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2023). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 7R01CA233662-05
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment
National Institutes of Health
Grant: 1R01CA236936-01A1
The role of glutaminolysis as a therapeutic target in T-ALL
National Institutes of Health
Grant: 1S10OD025140-01A1
An Orbitrap Tribrid mass spectrometer and nanoflow LC system to upgrade the proteomics facility at Rutgers-New Brunswick and Robert Wood Johnson Medical School
National Institutes of Health
Grant: 1S10OD012346-01A1
Supercomputing: Rutgers' Catalyst for Discovery at the Frontiers of Medicine
National Institutes of Health
Grant: 3P30CA072720-07S2
CANCER CENTER SUPPORT GRANT
Fields of Study
Keywords
Sustainable Development Goals